A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

O. A. Khan, M. Ranson, M. Michael, I. Olver, N. C. Levitt, P. Mortimer, A. J. Watson, G. P. Margison, R. Midgley, M. R. Middleton

    Research output: Contribution to journalArticlepeer-review

    Abstract

    To evaluate the tumour response to lomeguatrib and temozolomide (TMZ) administered for 5 consecutive days every 4 weeks in patients with metastatic colorectal carcinoma. Patients with stage IV metastatic colorectal carcinoma received lomeguatrib (40 mg) and TMZ (50-200 mg m-2) orally for 5 consecutive days every 4 weeks. Response was determined every two cycles. Pharmacokinetics of lomeguatrib and TMZ as well as their pharmacodynamic effects in peripheral blood mononuclear cells (PBMC) were determined. Nineteen patients received 49 cycles of treatments. Despite consistent depletion of O 6-methylguanine-DNA methyltransferase in PBMC, none of the patients responded to treatment. Three patients had stable disease, one for the duration of the study, and no fall in carcinoembryonic antigen was observed in any patient. Median time to progression was 50 days. The commonest adverse effects were gastrointestinal and haematological and these were comparable to those of TMZ when given alone. This combination of lomeguatrib and TMZ is not efficacious in metastatic colorectal cancer. If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated. © 2008 Cancer Research UK.
    Original languageEnglish
    Pages (from-to)1614-1618
    Number of pages4
    JournalBritish Journal of Cancer
    Volume98
    Issue number10
    DOIs
    Publication statusPublished - 20 May 2008

    Keywords

    • Colorectal cancer
    • DNA repair
    • Lomeguatrib
    • O6-methylguanine-DNA methyltransferase
    • Temozolomide

    Fingerprint

    Dive into the research topics of 'A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer'. Together they form a unique fingerprint.

    Cite this